Who are hyoscine-N-butyl bromide(HBB)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Cantabell Tab, Hyoscine butylbromide, Analgesics, Non-Narcotic.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/hyoscine-n-butyl-bromide-hbb.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

hyoscine-N-butyl bromide(HBB) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

hyoscine-N-butyl bromide(HBB) (hyoscine-N-butyl bromide(HBB)) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anticholinergic antispasmodic. Area: Gastroenterology.

marketed Anticholinergic antispasmodic Muscarinic acetylcholine receptors (M1-M5) Gastroenterology Small molecule Live · refreshed every 30 min

Target snapshot

hyoscine-N-butyl bromide(HBB) (hyoscine-N-butyl bromide(HBB)) — Sisli Hamidiye Etfal Training and Research Hospital. Hyoscine-N-butyl bromide is an anticholinergic agent that blocks muscarinic acetylcholine receptors to reduce smooth muscle spasms and secretions.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
hyoscine-N-butyl bromide(HBB) TARGET	hyoscine-N-butyl bromide(HBB)	Sisli Hamidiye Etfal Training and Research Hospital	marketed	Anticholinergic antispasmodic	Muscarinic acetylcholine receptors (M1-M5)
Cantabell Tab	Cantabell Tab	Chong Kun Dang Pharmaceutical	marketed	Anticholinergic antispasmodic	Muscarinic acetylcholine receptors
Hyoscine butylbromide, Analgesics, Non-Narcotic	Hyoscine butylbromide, Analgesics, Non-Narcotic	London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's	phase 3	Anticholinergic antispasmodic	Muscarinic acetylcholine receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anticholinergic antispasmodic class)

Chong Kun Dang Pharmaceutical · 1 drug in this class
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · 1 drug in this class
Sisli Hamidiye Etfal Training and Research Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). hyoscine-N-butyl bromide(HBB) — Competitive Intelligence Brief. https://druglandscape.com/ci/hyoscine-n-butyl-bromide-hbb. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab